1. Sequence specificity, reactivity, and antitumor activity of DNA-alkylating pyrrole-imidazole diamides.
- Author
-
Bando T, Iida H, Tao ZF, Narita A, Fukuda N, Yamori T, and Sugiyama H
- Subjects
- Alkylation, Antineoplastic Agents, Alkylating chemistry, Base Sequence, Cell Line, Tumor, Diamide chemistry, Diamide pharmacology, Drug Screening Assays, Antitumor, Duocarmycins, Gene Expression Profiling, Humans, Imidazoles chemistry, Imidazoles pharmacology, Indoles chemistry, Inhibitory Concentration 50, Molecular Sequence Data, Molecular Structure, Oligonucleotide Array Sequence Analysis, Pyrroles chemistry, Pyrroles pharmacology, Pyrrolidinones chemistry, Antineoplastic Agents, Alkylating pharmacology, DNA metabolism
- Abstract
Three conjugates of imidazole (Im)-pyrrole (Py) diamide and a DNA-alkylating moiety derived from the antibiotic duocarmycin A were synthesized, and their sequence specificity, reactivity, and antitumor activity comparatively examined. Sequencing gel analysis indicated that ImPyDu (1) alkylates DNA at the 3' end of AT-rich sequences at micromolar concentration. ImPyDu86 (2) reacts with DNA at AT-rich sites together with dialkylation sites at micromolar concentration. ImPyLDu86 (3) efficiently alkylates dialkylation sites at nanomolar concentration. Average values of log IC(50) against a 39 cancer cell line panel of 1-3 were -4.59, -5.95, and -8.25, respectively. The differential growth inhibition pattern of 1-3 varied with relatively low correlation coefficients. Array-based gene expression monitoring was performed for 3 in a human lung cancer cell line. Substantial downregulation of expression was seen for genes involved in DNA damage response, transcription, and signal transduction.
- Published
- 2003
- Full Text
- View/download PDF